President Trump has signed a new executive order aimed at clearing regulatory pathways for research into psychedelic substances as potential mental-health treatments. The order has been welcomed by advocates who see substances like psilocybin and MDMA as promising therapies for PTSD, depression, and addiction.
However, experts have urged caution, noting that the science is still evolving and that loosened regulations must be balanced with rigorous clinical standards. The order represents a notable bipartisan area of interest, as psychedelics research has attracted support from both sides of the political aisle.
